Simpler Grants.gov #361450

Forecasted Grant for Functional Target Validation in Alzheimer’s Disease–Related Dementias Research

This opportunity is a forecasted grant from the National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), to advance research in Alzheimer’s Disease–Related Dementias (ADRD): - Government Buyer: - National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) - Purpose: - Support ambitious research projects for comprehensive functional validation of newly identified therapeutic target candidates for ADRD - Address the lack of well-validated targets linked to disease mechanisms, a key barrier to effective ADRD treatments - Project Structure: - Phased award mechanism (e.g., R61/R33) - Phase 1: Develop technologies, models, and protocols to modulate candidate targets and assess physiological consequences in relevant in vitro and in vivo models - Phase 2: Upon meeting milestones, measure and cross-validate effects of target modulation across multiple experimental modalities and collaborating labs - Emphasis on NIH rigor and reproducibility guidelines - Products/Services Requested: - Research services for technology, model, and protocol development - Functional validation and cross-validation of therapeutic targets in ADRD - Notable Requirements: - Projects must demonstrate technical feasibility and proof-of-concept to advance to Phase 2 - Broad eligibility: U.S.-based nonprofits, government entities, educational institutions, and small businesses - Non-domestic (non-U.S.) entities are not eligible - No specific OEMs, vendors, or commercial products are named, as this is a research grant opportunity - Estimated funding is $1,800,000

Description

The National Institute of Neurological Disorders and Stroke (NINDS) seeks to support ambitious research projects for comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). The initiative aims to overcome barriers in developing effective treatments by ensuring rigorous target validation linked to disease mechanisms. It supports a phased award mechanism to develop technologies, models, and protocols to modulate candidate targets and assess their physiological consequences in relevant disease models. Successful projects will transition to a second phase focused on cross-validating target modulation effects across multiple experimental modalities and laboratories.

View original listing